Active 0 6 0 6 B-chronic_disease
infection 7 16 7 16 I-chronic_disease
with 17 21 17 21 O
human 22 27 22 27 B-chronic_disease
immunodeficiency 28 44 28 44 I-chronic_disease
virus 45 50 45 50 I-chronic_disease
( 51 52 51 52 I-chronic_disease
HIV 52 55 52 55 I-chronic_disease
) 55 56 55 56 I-chronic_disease
, 56 57 56 57 O
hepatitis 58 67 58 67 B-chronic_disease
B 68 69 68 69 I-chronic_disease
virus 70 75 70 75 I-chronic_disease
( 76 77 76 77 I-chronic_disease
HBV 77 80 77 80 I-chronic_disease
) 80 81 80 81 I-chronic_disease
, 81 82 81 82 O
hepatitis 83 92 83 92 B-chronic_disease
C 93 94 93 94 I-chronic_disease
virus 95 100 95 100 I-chronic_disease
( 101 102 101 102 I-chronic_disease
HCV 102 105 102 105 I-chronic_disease
) 105 106 105 106 I-chronic_disease
or 107 109 107 109 O
human 110 115 110 115 B-chronic_disease
T 116 117 116 117 I-chronic_disease
- 117 118 117 118 I-chronic_disease
cell 118 122 118 122 I-chronic_disease
lymphotropic 123 135 123 135 I-chronic_disease
virus 136 141 136 141 I-chronic_disease
( 142 143 142 143 I-chronic_disease
HTLV 143 147 143 147 I-chronic_disease
) 147 148 147 148 I-chronic_disease
as 149 151 149 151 O
minimally 152 161 152 161 O
defined 162 169 162 169 O
below 170 175 170 175 O
: 175 176 175 176 O
a 177 178 177 178 O
) 178 179 178 179 O
Positive 180 188 180 188 O
serology 189 197 189 197 O
for 198 201 198 201 O
HIV 202 205 202 205 O
. 205 206 205 206 O
b 207 208 207 208 O
) 208 209 208 209 O
Active 210 216 210 216 B-chronic_disease
hepatitis 217 226 217 226 I-chronic_disease
B 227 228 227 228 I-chronic_disease
infection 229 238 229 238 I-chronic_disease
as 239 241 239 241 O
determined 242 252 242 252 O
by 253 255 253 255 O
hepatitis 256 265 256 265 O
B 266 267 266 267 O
surface 268 275 268 275 O
antigen 276 283 276 283 O
. 283 284 283 284 O
c 285 286 285 286 O
) 286 287 286 287 O
Active 288 294 288 294 B-chronic_disease
hepatitis 295 304 295 304 I-chronic_disease
C 305 306 305 306 I-chronic_disease
infection 307 316 307 316 I-chronic_disease
as 317 319 317 319 O
determined 320 330 320 330 O
by 331 333 331 333 O
hepatitis 334 343 334 343 O
C 344 345 344 345 O
RNA 346 349 346 349 O
; 349 350 349 350 O
A 351 352 351 352 O
subject 353 360 353 360 O
who 361 364 361 364 O
is 365 367 365 367 O
HCV 368 371 368 371 B-treatment
antibody 372 380 372 380 I-treatment
positive 381 389 381 389 O
will 390 394 390 394 O
be 395 397 395 397 O
screened 398 406 398 406 O
for 407 410 407 410 O
HCV 411 414 411 414 O
ribonucleic 415 426 415 426 O
acid 427 431 427 431 O
( 432 433 432 433 O
RNA 433 436 433 436 O
) 436 437 436 437 O
by 438 440 438 440 O
any 441 444 441 444 O
reverse 445 452 445 452 O
transcriptase 453 466 453 466 O
( 467 468 467 468 O
RT 468 470 468 470 O
) 470 471 470 471 O
polymerase 472 482 472 482 O
chain 483 488 483 488 O
reaction 489 497 489 497 O
( 498 499 498 499 O
PCR 499 502 499 502 O
) 502 503 502 503 O
or 504 506 504 506 O
bDNA 507 511 507 511 O
assay 512 517 512 517 O
. 517 518 517 518 O
If 519 521 519 521 O
HCV 522 525 522 525 O
antibody 526 534 526 534 O
is 535 537 535 537 O
positive 538 546 538 546 O
, 546 547 546 547 O
eligibility 548 559 548 559 O
will 560 564 560 564 O
be 565 567 565 567 O
determined 568 578 568 578 O
based 579 584 579 584 O
on 585 587 585 587 O
a 588 589 588 589 O
negative 590 598 590 598 O
screening 599 608 599 608 O
RNA 609 612 609 612 O
value 613 618 613 618 O
. 618 619 618 619 O
d 620 621 620 621 O
) 621 622 621 622 O
Positive 623 631 623 631 O
serology 632 640 632 640 O
for 641 644 641 644 O
HTLV 645 649 645 649 B-chronic_disease
1 650 651 650 651 I-chronic_disease
or 652 654 652 654 I-chronic_disease
2 655 656 655 656 I-chronic_disease

Contraceptive 0 13 657 670 O
use 14 17 671 674 O
by 18 20 675 677 O
men 21 24 678 681 B-gender
or 25 27 682 684 O
women 28 33 685 690 B-gender
should 34 40 691 697 O
be 41 43 698 700 O
consistent 44 54 701 711 O
with 55 59 712 716 O
local 60 65 717 722 O
regulations 66 77 723 734 O
regarding 78 87 735 744 O
the 88 91 745 748 O
methods 92 99 749 756 O
of 100 102 757 759 O
contraception 103 116 760 773 O
for 117 120 774 777 O
those 121 126 778 783 O
participating 127 140 784 797 O
in 141 143 798 800 O
clinical 144 152 801 809 O
studies 153 160 810 817 O
. 160 161 817 818 O
Male 162 166 819 823 B-gender
subjects 167 175 824 832 I-gender
: 175 176 832 833 O
Male 177 181 834 838 O
subjects 182 190 839 847 O
are 191 194 848 851 O
eligible 195 203 852 860 O
to 204 206 861 863 O
participate 207 218 864 875 O
if 219 221 876 878 O
they 222 226 879 883 O
agree 227 232 884 889 O
to 233 235 890 892 O
the 236 239 893 896 O
following 240 249 897 906 O
during 250 256 907 913 O
the 257 260 914 917 O
intervention 261 273 918 930 O
period 274 280 931 937 O
starting 281 289 938 946 O
at 290 292 947 949 O
the 293 296 950 953 O
first 297 302 954 959 O
dose 303 307 960 964 O
of 308 310 965 967 O
chemotherapy 311 323 968 980 B-treatment
for 324 327 981 984 O
at 328 330 985 987 O
least 331 336 988 993 O
12 337 339 994 996 B-lower_bound
months 340 346 997 1003 I-lower_bound
after 347 352 1004 1009 I-lower_bound
receiving 353 362 1010 1019 O
the 363 366 1020 1023 O
T 367 368 1024 1025 B-treatment
- 368 369 1025 1026 I-treatment
cell 369 373 1026 1030 I-treatment
infusion 374 382 1031 1039 I-treatment
, 382 383 1039 1040 O
or 384 386 1041 1043 O
4 387 388 1044 1045 O
months 389 395 1046 1052 O
after 396 401 1053 1058 O
there 402 407 1059 1064 O
is 408 410 1065 1067 O
no 411 413 1068 1070 O
evidence 414 422 1071 1079 O
of 423 425 1080 1082 O
persistence/ 426 438 1083 1095 O
gene 439 443 1096 1100 O
modified 444 452 1101 1109 O
cells 453 458 1110 1115 O
in 459 461 1116 1118 O
the 462 465 1119 1122 O
subject 466 473 1123 1130 O
's 473 475 1130 1132 O
blood 476 481 1133 1138 O
, 481 482 1138 1139 O
whichever 483 492 1140 1149 O
is 493 495 1150 1152 O
longer 496 502 1153 1159 O
. 502 503 1159 1160 O
A 504 505 1161 1162 O
) 505 506 1162 1163 O
Refrain 507 514 1164 1171 O
from 515 519 1172 1176 O
donating 520 528 1177 1185 O
sperm 529 534 1186 1191 O
Plus 535 539 1192 1196 O
either 540 546 1197 1203 O
: 546 547 1203 1204 O
B 548 549 1205 1206 O
) 549 550 1206 1207 O
Be 551 553 1208 1210 B-contraception_consent
abstinent 554 563 1211 1220 I-contraception_consent
from 564 568 1221 1225 I-contraception_consent
heterosexual 569 581 1226 1238 I-contraception_consent
or 582 584 1239 1241 I-contraception_consent
homosexual 585 595 1242 1252 I-contraception_consent
intercourse 596 607 1253 1264 I-contraception_consent
as 608 610 1265 1267 O
their 611 616 1268 1273 O
preferred 617 626 1274 1283 O
and 627 630 1284 1287 O
usual 631 636 1288 1293 O
lifestyle 637 646 1294 1303 O
( 647 648 1304 1305 O
abstinent 648 657 1305 1314 O
on 658 660 1315 1317 O
a 661 662 1318 1319 O
long 663 667 1320 1324 O
term 668 672 1325 1329 O
and 673 676 1330 1333 O
persistent 677 687 1334 1344 O
basis 688 693 1345 1350 O
) 693 694 1350 1351 O
and 695 698 1352 1355 O
agree 699 704 1356 1361 B-contraception_consent
to 705 707 1362 1364 I-contraception_consent
remain 708 714 1365 1371 I-contraception_consent
abstinent 715 724 1372 1381 I-contraception_consent
OR 725 727 1382 1384 O
C 728 729 1385 1386 O
) 729 730 1386 1387 O
Must 731 735 1388 1392 O
agree 736 741 1393 1398 B-contraception_consent
to 742 744 1399 1401 I-contraception_consent
use 745 748 1402 1405 I-contraception_consent
contraception 749 762 1406 1419 I-contraception_consent
/ 762 763 1419 1420 I-contraception_consent
barrier 763 770 1420 1427 I-contraception_consent
. 770 771 1427 1428 O
Female 772 778 1429 1435 B-gender
subjects 779 787 1436 1444 I-gender
: 787 788 1444 1445 O
A 789 790 1446 1447 O
female 791 797 1448 1454 B-gender
subject 798 805 1455 1462 I-gender
is 806 808 1463 1465 O
eligible 809 817 1466 1474 O
to 818 820 1475 1477 O
participate 821 832 1478 1489 O
if 833 835 1490 1492 O
she 836 839 1493 1496 O
is 840 842 1497 1499 O
not 843 846 1500 1503 B-pregnancy
pregnant 847 855 1504 1512 I-pregnancy
or 856 858 1513 1515 O
breastfeeding 859 872 1516 1529 O
, 872 873 1529 1530 O
and 874 877 1531 1534 O
at 878 880 1535 1537 O
least 881 886 1538 1543 O
one 887 890 1544 1547 B-lower_bound
of 891 893 1548 1550 O
the 894 897 1551 1554 O
following 898 907 1555 1564 O
conditions 908 918 1565 1575 O
applies 919 926 1576 1583 O
: 926 927 1583 1584 O
Is 928 930 1585 1587 O
not 931 934 1588 1591 O
a 935 936 1592 1593 O
woman 937 942 1594 1599 B-gender
of 943 945 1600 1602 O
childbearing 946 958 1603 1615 O
potential 959 968 1616 1625 O
( 969 970 1626 1627 O
WOCBP 970 975 1627 1632 O
) 975 976 1632 1633 O
OR 977 979 1634 1636 O
Is 980 982 1637 1639 O
a 983 984 1640 1641 O
WOCBP 985 990 1642 1647 O
who 991 994 1648 1651 O
will 995 999 1652 1656 O
agree 1000 1005 1657 1662 B-contraception_consent
to 1006 1008 1663 1665 I-contraception_consent
use 1009 1012 1666 1669 I-contraception_consent
a 1013 1014 1670 1671 I-contraception_consent
barrier 1015 1022 1672 1679 I-contraception_consent
method 1023 1029 1680 1686 I-contraception_consent
( 1030 1031 1687 1688 I-contraception_consent
male 1031 1035 1688 1692 I-contraception_consent
condom 1036 1042 1693 1699 I-contraception_consent
) 1042 1043 1699 1700 I-contraception_consent
and 1044 1047 1701 1704 I-contraception_consent
use 1048 1051 1705 1708 I-contraception_consent
a 1052 1053 1709 1710 I-contraception_consent
contraceptive 1054 1067 1711 1724 I-contraception_consent
method 1068 1074 1725 1731 I-contraception_consent
that 1075 1079 1732 1736 O
is 1080 1082 1737 1739 O
highly 1083 1089 1740 1746 O
effective 1090 1099 1747 1756 O
during 1100 1106 1757 1763 O
the 1107 1110 1764 1767 O
intervention 1111 1123 1768 1780 O
period 1124 1130 1781 1787 O
and 1131 1134 1788 1791 O
for 1135 1138 1792 1795 O
at 1139 1141 1796 1798 O
least 1142 1147 1799 1804 O
12 1148 1150 1805 1807 O
months 1151 1157 1808 1814 O
after 1158 1163 1815 1820 O
receiving 1164 1173 1821 1830 O
the 1174 1177 1831 1834 O
T 1178 1179 1835 1836 O
- 1179 1180 1836 1837 O
cell 1180 1184 1837 1841 O
infusion 1185 1193 1842 1850 O
, 1193 1194 1850 1851 O
or 1195 1197 1852 1854 O
4 1198 1199 1855 1856 O
months 1200 1206 1857 1863 O
after 1207 1212 1864 1869 O
there 1213 1218 1870 1875 O
is 1219 1221 1876 1878 O
no 1222 1224 1879 1881 O
evidence 1225 1233 1882 1890 O
of 1234 1236 1891 1893 O
persistence/ 1237 1249 1894 1906 O
gene 1250 1254 1907 1911 O
modified 1255 1263 1912 1920 O
cells 1264 1269 1921 1926 O
in 1270 1272 1927 1929 O
the 1273 1276 1930 1933 O
subject 1277 1284 1934 1941 O
's 1284 1286 1941 1943 O
blood 1287 1292 1944 1949 O
, 1292 1293 1949 1950 O
whichever 1294 1303 1951 1960 O
is 1304 1306 1961 1963 O
longer 1307 1313 1964 1970 O
. 1313 1314 1970 1971 O
WOCBP 1315 1320 1972 1977 O
should 1321 1327 1978 1984 O
also 1328 1332 1985 1989 O
agree 1333 1338 1990 1995 O
not 1339 1342 1996 1999 O
to 1343 1345 2000 2002 O
donate 1346 1352 2003 2009 O
eggs 1353 1357 2010 2014 O
( 1358 1359 2015 2016 O
ova 1359 1362 2016 2019 O
, 1362 1363 2019 2020 O
oocytes 1364 1371 2021 2028 O
) 1371 1372 2028 2029 O
for 1373 1376 2030 2033 O
the 1377 1380 2034 2037 O
purpose 1381 1388 2038 2045 O
of 1389 1391 2046 2048 O
reproduction 1392 1404 2049 2061 O
during 1405 1411 2062 2068 O
this 1412 1416 2069 2073 O
period 1417 1423 2074 2080 O
. 1423 1424 2080 2081 O
The 1425 1428 2082 2085 O
Investigator 1429 1441 2086 2098 O
should 1442 1448 2099 2105 O
evaluate 1449 1457 2106 2114 O
the 1458 1461 2115 2118 O
effectiveness 1462 1475 2119 2132 O
of 1476 1478 2133 2135 O
the 1479 1482 2136 2139 O
contraceptive 1483 1496 2140 2153 O
method 1497 1503 2154 2160 O
in 1504 1506 2161 2163 O
relationship 1507 1519 2164 2176 O
to 1520 1522 2177 2179 O
the 1523 1526 2180 2183 O
first 1527 1532 2184 2189 O
dose 1533 1537 2190 2194 O
of 1538 1540 2195 2197 O
study 1541 1546 2198 2203 O
intervention 1547 1559 2204 2216 O

Corrected 0 9 2217 2226 O
QT 10 12 2227 2229 B-clinical_variable
interval 13 21 2230 2238 I-clinical_variable
( 22 23 2239 2240 I-clinical_variable
QTc 23 26 2240 2243 I-clinical_variable
) 26 27 2243 2244 I-clinical_variable
> 28 29 2245 2246 O
450 29 32 2246 2249 B-lower_bound
milliseconds 33 45 2250 2262 I-lower_bound
( 46 47 2263 2264 I-lower_bound
msec 47 51 2264 2268 I-lower_bound
) 51 52 2268 2269 I-lower_bound
or 53 55 2270 2272 O
QTc 56 59 2273 2276 O
> 60 61 2277 2278 O
480 61 64 2278 2281 B-lower_bound
msec 65 69 2282 2286 I-lower_bound
for 70 73 2287 2290 O
subjects 74 82 2291 2299 O
with 83 87 2300 2304 O
Bundle 88 94 2305 2311 B-chronic_disease
Branch 95 101 2312 2318 I-chronic_disease
Block 102 107 2319 2324 I-chronic_disease
( 108 109 2325 2326 I-chronic_disease
BBB 109 112 2326 2329 I-chronic_disease
) 112 113 2329 2330 I-chronic_disease

Current 0 7 2331 2338 O
active 8 14 2339 2345 B-chronic_disease
liver 15 20 2346 2351 I-chronic_disease
or 21 23 2352 2354 I-chronic_disease
biliary 24 31 2355 2362 I-chronic_disease
disease 32 39 2363 2370 I-chronic_disease
( 40 41 2371 2372 O
with 41 45 2372 2376 O
the 46 49 2377 2380 O
exception 50 59 2381 2390 O
of 60 62 2391 2393 O
Gilbert 63 70 2394 2401 B-chronic_disease
's 70 72 2401 2403 I-chronic_disease
syndrome 73 81 2404 2412 I-chronic_disease
or 82 84 2413 2415 O
asymptomatic 85 97 2416 2428 B-chronic_disease
gallstones 98 108 2429 2439 I-chronic_disease
, 108 109 2439 2440 O
liver 110 115 2441 2446 B-cancer
metastases 116 126 2447 2457 I-cancer
or 127 129 2458 2460 O
otherwise 130 139 2461 2470 O
stable 140 146 2471 2477 O
chronic 147 154 2478 2485 B-chronic_disease
liver 155 160 2486 2491 I-chronic_disease
disease 161 168 2492 2499 I-chronic_disease
per 169 172 2500 2503 O
Investigator 173 185 2504 2516 O
assessment 186 196 2517 2527 O
) 196 197 2527 2528 O
. 197 198 2528 2529 O
Stable 199 205 2530 2536 O
chronic 206 213 2537 2544 O
liver 214 219 2545 2550 O
disease 220 227 2551 2558 O
should 228 234 2559 2565 O
generally 235 244 2566 2575 O
be 245 247 2576 2578 O
defined 248 255 2579 2586 O
by 256 258 2587 2589 O
the 259 262 2590 2593 O
absence 263 270 2594 2601 O
of 271 273 2602 2604 O
ascites 274 281 2605 2612 B-chronic_disease
, 281 282 2612 2613 O
encephalopathy 283 297 2614 2628 B-chronic_disease
, 297 298 2628 2629 O
coagulopathy 299 311 2630 2642 B-chronic_disease
, 311 312 2642 2643 O
hypoalbuminemia 313 328 2644 2659 B-chronic_disease
, 328 329 2659 2660 O
esophageal 330 340 2661 2671 B-chronic_disease
or 341 343 2672 2674 I-chronic_disease
gastric 344 351 2675 2682 I-chronic_disease
varices 352 359 2683 2690 I-chronic_disease
, 359 360 2690 2691 O
persistent 361 371 2692 2702 O
jaundice 372 380 2703 2711 O
or 381 383 2712 2714 O
cirrhosis 384 393 2715 2724 B-chronic_disease

Exceptions 0 10 2725 2735 O
: 10 11 2735 2736 O
adequately 12 22 2737 2747 O
treated 23 30 2748 2755 O
malignancies 31 43 2756 2768 B-cancer
not 44 47 2769 2772 O
likely 48 54 2773 2779 O
to 55 57 2780 2782 O
require 58 65 2783 2790 O
therapy 66 73 2791 2798 B-treatment
( 74 75 2799 2800 O
e.g. 75 79 2800 2804 O
, 79 80 2804 2805 O
completely 81 91 2806 2816 O
resected 92 100 2817 2825 O
non 101 104 2826 2829 B-cancer
- 104 105 2829 2830 I-cancer
melanomatous 105 117 2830 2842 I-cancer
skin 118 122 2843 2847 I-cancer
carcinoma 123 132 2848 2857 I-cancer
or 133 135 2858 2860 O
successfully 136 148 2861 2873 O
treated 149 156 2874 2881 O
in 157 159 2882 2884 B-cancer
situ 160 164 2885 2889 I-cancer
carcinoma 165 174 2890 2899 I-cancer
) 174 175 2899 2900 O

Female 0 6 2901 2907 B-gender

History 0 7 2908 2915 O
of 8 10 2916 2918 O
allergic 11 19 2919 2927 O
reactions 20 29 2928 2937 O
attributed 30 40 2938 2948 O
to 41 43 2949 2951 O
compounds 44 53 2952 2961 O
of 54 56 2962 2964 O
similar 57 64 2965 2972 O
chemical 65 73 2973 2981 O
or 74 76 2982 2984 O
biologic 77 85 2985 2993 O
composition 86 97 2994 3005 O
to 98 100 3006 3008 O
cyclophosphamide 101 117 3009 3025 B-allergy_name
, 117 118 3025 3026 O
fludarabine 119 130 3027 3038 B-allergy_name
, 130 131 3038 3039 O
or 132 134 3040 3042 O
other 135 140 3043 3048 O
agents 141 147 3049 3055 O
used 148 152 3056 3060 O
in 153 155 3061 3063 O
the 156 159 3064 3067 O
study 160 165 3068 3073 O

History 0 7 3074 3081 O
of 8 10 3082 3084 O
chronic 11 18 3085 3092 O
or 19 21 3093 3095 O
recurrent 22 31 3096 3105 O
( 32 33 3106 3107 O
within 33 39 3107 3113 O
the 40 43 3114 3117 O
last 44 48 3118 3122 O
year 49 53 3123 3127 O
prior 54 59 3128 3133 O
to 60 62 3134 3136 O
enrollment 63 73 3137 3147 O
) 73 74 3147 3148 O
severe 75 81 3149 3155 O
autoimmune 82 92 3156 3166 B-chronic_disease
or 93 95 3167 3169 O
active 96 102 3170 3176 O
immune 103 109 3177 3183 B-chronic_disease
- 109 110 3183 3184 I-chronic_disease
mediated 110 118 3184 3192 I-chronic_disease
disease 119 126 3193 3200 I-chronic_disease
requiring 127 136 3201 3210 O
steroids 137 145 3211 3219 B-treatment
or 146 148 3220 3222 O
other 149 154 3223 3228 O
immunosuppressive 155 172 3229 3246 B-treatment
treatments 173 183 3247 3257 I-treatment

Immune 0 6 3258 3264 B-treatment
therapy 7 14 3265 3272 I-treatment
( 15 16 3273 3274 O
including 16 25 3274 3283 O
monoclonal 26 36 3284 3294 B-treatment
antibody 37 45 3295 3303 I-treatment
therapy 46 53 3304 3311 I-treatment
, 53 54 3311 3312 O
checkpoint 55 65 3313 3323 O
inhibitors 66 76 3324 3334 O
) 76 77 3334 3335 O
or 78 80 3336 3338 O
biological 81 91 3339 3349 B-treatment
therapy 92 99 3350 3357 I-treatment
with 100 104 3358 3362 O
no 105 107 3363 3365 O
wash 108 112 3366 3370 O
- 112 113 3370 3371 O
out 113 116 3371 3374 O
times 117 122 3375 3380 O
required 123 131 3381 3389 O

Investigational 0 15 3390 3405 B-treatment
treatment 16 25 3406 3415 I-treatment
within 26 32 3416 3422 O
4 33 34 3423 3424 B-upper_bound
weeks 35 40 3425 3430 I-upper_bound
prior 41 46 3431 3436 I-upper_bound
to 47 49 3437 3439 O
leukapheresis 50 63 3440 3453 B-treatment
; 63 64 3453 3454 O
experimental 65 77 3455 3467 B-treatment
anti 78 82 3468 3472 I-treatment
- 82 83 3472 3473 I-treatment
cancer 83 89 3473 3479 I-treatment
vaccine 90 97 3480 3487 I-treatment
within 98 104 3488 3494 O
2 105 106 3495 3496 B-upper_bound
months 107 113 3497 3503 I-upper_bound
prior 114 119 3504 3509 I-upper_bound
to 120 122 3510 3512 O
leukapheresis 123 136 3513 3526 O
in 137 139 3527 3529 O
the 140 143 3530 3533 O
absence 144 151 3534 3541 O
of 152 154 3542 3544 O
response 155 163 3545 3553 O
or 164 166 3554 3556 O
in 167 169 3557 3559 O
the 170 173 3560 3563 O
opinion 174 181 3564 3571 O
of 182 184 3572 3574 O
the 185 188 3575 3578 O
Investigator 189 201 3579 3591 O
is 202 204 3592 3594 O
responding 205 215 3595 3605 O
to 216 218 3606 3608 O
an 219 221 3609 3611 O
experimental 222 234 3612 3624 B-treatment
vaccine 235 242 3625 3632 I-treatment
given 243 248 3633 3638 O
within 249 255 3639 3645 O
6 256 257 3646 3647 B-upper_bound
months 258 264 3648 3654 I-upper_bound
prior 265 270 3655 3660 I-upper_bound
to 271 273 3661 3663 O
leukapheresis 274 287 3664 3677 O
; 287 288 3677 3678 O
any 289 292 3679 3682 O
prior 293 298 3683 3688 B-treatment
gene 299 303 3689 3693 I-treatment
therapy 304 311 3694 3701 I-treatment
using 312 317 3702 3707 I-treatment
an 318 320 3708 3710 I-treatment
integrating 321 332 3711 3722 I-treatment
vector 333 339 3723 3729 I-treatment

Male 0 4 3730 3734 B-gender

Other 0 5 3735 3740 O
active 6 12 3741 3747 O
malignancies 13 25 3748 3760 B-cancer
besides 26 33 3761 3768 O
NSCLC 34 39 3769 3774 B-cancer
within 40 46 3775 3781 O
3 47 48 3782 3783 B-upper_bound
years 49 54 3784 3789 I-upper_bound
prior 55 60 3790 3795 I-upper_bound
to 61 63 3796 3798 O
Screening 64 73 3799 3808 O

Subject 0 7 3809 3816 O
has 8 11 3817 3820 O
Eastern 12 19 3821 3828 B-clinical_variable
Cooperative 20 31 3829 3840 I-clinical_variable
Oncology 32 40 3841 3849 I-clinical_variable
Group 41 46 3850 3855 I-clinical_variable
( 47 48 3856 3857 I-clinical_variable
ECOG 48 52 3857 3861 I-clinical_variable
) 52 53 3861 3862 I-clinical_variable
Performance 54 65 3863 3874 I-clinical_variable
Status 66 72 3875 3881 I-clinical_variable
0 73 74 3882 3883 B-lower_bound
- 74 75 3883 3884 O
1 75 76 3884 3885 B-upper_bound
10 77 79 3886 3888 O
. 79 80 3888 3889 O
Subject 81 88 3890 3897 O
has 89 92 3898 3901 O
an 93 95 3902 3904 O
anticipated 96 107 3905 3916 O
life 108 112 3917 3921 B-clinical_variable
expectancy 113 123 3922 3932 I-clinical_variable
> 124 125 3933 3934 O
3 125 126 3934 3935 B-lower_bound
months 127 133 3936 3942 I-lower_bound

Subject 0 7 3943 3950 O
has 8 11 3951 3954 O
a 12 13 3955 3956 O
diagnosis 14 23 3957 3966 O
of 24 26 3967 3969 O
histologically 27 41 3970 3984 O
or 42 44 3985 3987 O
cytologically 45 58 3988 4001 O
confirmed 59 68 4002 4011 O
advanced 69 77 4012 4020 O
non 78 81 4021 4024 B-cancer
- 81 82 4024 4025 I-cancer
small 82 87 4025 4030 I-cancer
cell 88 92 4031 4035 I-cancer
lung 93 97 4036 4040 I-cancer
cancer 98 104 4041 4047 I-cancer
( 105 106 4048 4049 O
Stage 106 111 4049 4054 B-lower_bound
IIIB 112 116 4055 4059 I-lower_bound
or 117 119 4060 4062 O
IV 120 122 4063 4065 B-upper_bound
) 122 123 4065 4066 O
or 124 126 4067 4069 O
recurrent 127 136 4070 4079 O
disease 137 144 4080 4087 O

Subject 0 7 4088 4095 O
has 8 11 4096 4099 O
active 12 18 4100 4106 O
brain 19 24 4107 4112 B-cancer
metastases 25 35 4113 4123 I-cancer
or 36 38 4124 4126 O
leptomeningeal 39 53 4127 4141 B-cancer
metastases 54 64 4142 4152 I-cancer

Subject 0 7 4153 4160 O
has 8 11 4161 4164 O
active 12 18 4165 4171 O
brain 19 24 4172 4177 B-cancer
metastases 25 35 4178 4188 I-cancer
or 36 38 4189 4191 O
leptomeningeal 39 53 4192 4206 B-cancer
metastases 54 64 4207 4217 I-cancer
. 64 65 4217 4218 O
Subjects 66 74 4219 4227 O
with 75 79 4228 4232 O
prior 80 85 4233 4238 O
history 86 93 4239 4246 O
of 94 96 4247 4249 O
brain 97 102 4250 4255 B-cancer
metastasis 103 113 4256 4266 I-cancer
who 114 117 4267 4270 O
have 118 122 4271 4275 O
undergone 123 132 4276 4285 O
local 133 138 4286 4291 B-treatment
therapy 139 146 4292 4299 I-treatment
( 147 148 4300 4301 O
i.e. 148 152 4301 4305 O
, 152 153 4305 4306 O
metastatectomy 154 168 4307 4321 B-treatment
and/or 169 175 4322 4328 O
radiation 176 185 4329 4338 B-treatment
) 185 186 4338 4339 O
and 187 190 4340 4343 O
show 191 195 4344 4348 O
no 196 198 4349 4351 O
evidence 199 207 4352 4360 O
of 208 210 4361 4363 O
local 211 216 4364 4369 O
recurrence 217 227 4370 4380 O
or 228 230 4381 4383 O
progression 231 242 4384 4395 O
over 243 247 4396 4400 O
the 248 251 4401 4404 O
past 252 256 4405 4409 B-upper_bound
3 257 258 4410 4411 I-upper_bound
months 259 265 4412 4418 I-upper_bound
prior 266 271 4419 4424 I-upper_bound
to 272 274 4425 4427 O
Screening 275 284 4428 4437 O
are 285 288 4438 4441 O
eligible 289 297 4442 4450 O

Subject 0 7 4451 4458 O
has 8 11 4459 4462 O
left 12 16 4463 4467 B-clinical_variable
ventricular 17 28 4468 4479 I-clinical_variable
ejection 29 37 4480 4488 I-clinical_variable
fraction 38 46 4489 4497 I-clinical_variable
> 47 48 4498 4499 O
= 48 49 4499 4500 O
50 49 51 4500 4502 B-lower_bound
% 51 52 4502 4503 I-lower_bound

Subject 0 7 4504 4511 O
is 8 10 4512 4514 O
> 11 12 4515 4516 O
= 12 13 4516 4517 O
18 13 15 4517 4519 B-lower_bound
years 16 21 4520 4525 I-lower_bound
of 22 24 4526 4528 O
age 25 28 4529 4532 B-age
on 29 31 4533 4535 O
the 32 35 4536 4539 O
day 36 39 4540 4543 O
of 40 42 4544 4546 O
signing 43 50 4547 4554 O
informed 51 59 4555 4563 O
consent 60 67 4564 4571 O

Subject 0 7 4572 4579 O
is 8 10 4580 4582 O
fit 11 14 4583 4586 O
for 15 18 4587 4590 O
leukapheresis 19 32 4591 4604 B-treatment
and 33 36 4605 4608 O
has 37 40 4609 4612 O
adequate 41 49 4613 4621 O
venous 50 56 4622 4628 O
access 57 63 4629 4635 O
for 64 67 4636 4639 O
the 68 71 4640 4643 O
cell 72 76 4644 4648 O
collection 77 87 4649 4659 O

Subject 0 7 4660 4667 O
is 8 10 4668 4670 O
pregnant 11 19 4671 4679 B-pregnancy
or 20 22 4680 4682 O
breastfeeding 23 36 4683 4696 O
. 36 37 4696 4697 O
Furthermore 38 49 4698 4709 O
and 50 53 4710 4713 O
prior 54 59 4714 4719 O
to 60 62 4720 4722 O
lymphodepleting 63 78 4723 4738 B-treatment
chemotherapy 79 91 4739 4751 I-treatment
, 91 92 4751 4752 O
a 93 94 4753 4754 O
subject 95 102 4755 4762 O
meeting 103 110 4763 4770 O
the 111 114 4771 4774 O
following 115 124 4775 4784 O
criteria 125 133 4785 4793 O
is 134 136 4794 4796 O
not 137 140 4797 4800 O
eligible 141 149 4801 4809 O
for 150 153 4810 4813 O
participation 154 167 4814 4827 O
in 168 170 4828 4830 O
the 171 174 4831 4834 O
study 175 180 4835 4840 O
: 180 181 4840 4841 O
1 182 183 4842 4843 O
) 183 184 4843 4844 O
Subject 185 192 4845 4852 O
has 193 196 4853 4856 O
received 197 205 4857 4865 O
: 205 206 4865 4866 O
Cytotoxic 207 216 4867 4876 B-treatment
chemotherapy 217 229 4877 4889 I-treatment
within 230 236 4890 4896 O
3 237 238 4897 4898 B-upper_bound
weeks 239 244 4899 4904 I-upper_bound
prior 245 250 4905 4910 I-upper_bound
to 251 253 4911 4913 O
lymphodepleting 254 269 4914 4929 O
chemotherapy 270 282 4930 4942 O
; 282 283 4942 4943 O
Immune 284 290 4944 4950 B-treatment
therapy 291 298 4951 4958 I-treatment
( 299 300 4959 4960 O
including 300 309 4960 4969 O
monoclonal 310 320 4970 4980 B-treatment
antibody 321 329 4981 4989 I-treatment
therapy 330 337 4990 4997 I-treatment
, 337 338 4997 4998 O
checkpoint 339 349 4999 5009 B-treatment
inhibitors 350 360 5010 5020 I-treatment
) 360 361 5020 5021 O
or 362 364 5022 5024 O
biological 365 375 5025 5035 B-treatment
therapy 376 383 5036 5043 I-treatment
within 384 390 5044 5050 O
4 391 392 5051 5052 B-upper_bound
weeks 393 398 5053 5058 I-upper_bound
prior 399 404 5059 5064 I-upper_bound
lymphodepleting 405 420 5065 5080 O
chemotherapy 421 433 5081 5093 O
; 433 434 5093 5094 O
Corticosteroids 435 450 5095 5110 B-treatment
or 451 453 5111 5113 O
any 454 457 5114 5117 O
other 458 463 5118 5123 O
immunosuppressive 464 481 5124 5141 B-treatment
therapy 482 489 5142 5149 I-treatment
within 490 496 5150 5156 O
2 497 498 5157 5158 B-upper_bound
weeks 499 504 5159 5164 I-upper_bound
prior 505 510 5165 5170 I-upper_bound
to 511 513 5171 5173 O
lymphodepleting 514 529 5174 5189 O
chemotherapy 530 542 5190 5202 O
; 542 543 5202 5203 O
Tyrosine 544 552 5204 5212 B-treatment
kinase 553 559 5213 5219 I-treatment
inhibitor 560 569 5220 5229 I-treatment
( 570 571 5230 5231 O
e.g. 571 575 5231 5235 O
erlotinib 576 585 5236 5245 B-treatment
, 585 586 5245 5246 O
gefitinib 587 596 5247 5256 B-treatment
) 596 597 5256 5257 O
and 598 601 5258 5261 O
any 602 605 5262 5265 O
other 606 611 5266 5271 O
anti 612 616 5272 5276 B-treatment
- 616 617 5276 5277 I-treatment
cancer 617 623 5277 5283 I-treatment
treatment 624 633 5284 5293 I-treatment
within 634 640 5294 5300 O
1 641 642 5301 5302 B-upper_bound
week 643 647 5303 5307 I-upper_bound
prior 648 653 5308 5313 I-upper_bound
to 654 656 5314 5316 O
lymphodepleting 657 672 5317 5332 O
chemotherapy 673 685 5333 5345 O
; 685 686 5345 5346 O
Major 687 692 5347 5352 B-treatment
surgery 693 700 5353 5360 I-treatment
within 701 707 5361 5367 O
4 708 709 5368 5369 O
weeks 710 715 5370 5375 O
prior 716 721 5376 5381 O
to 722 724 5382 5384 O
lymphodepleting 725 740 5385 5400 O
chemotherapy 741 753 5401 5413 O
; 753 754 5413 5414 O
subjects 755 763 5415 5423 O
must 764 768 5424 5428 O
have 769 773 5429 5433 O
recovered 774 783 5434 5443 O
from 784 788 5444 5448 O
any 789 792 5449 5452 O
surgical 793 801 5453 5461 O
- 801 802 5461 5462 O
related 802 809 5462 5469 O
toxicities 810 820 5470 5480 O
in 821 823 5481 5483 O
the 824 827 5484 5487 O
opinion 828 835 5488 5495 O
of 836 838 5496 5498 O
the 839 842 5499 5502 O
Investigator 843 855 5503 5515 O
; 855 856 5515 5516 O
Radiotherapy 857 869 5517 5529 B-treatment
that 870 874 5530 5534 O
involves 875 883 5535 5543 O
the 884 887 5544 5547 O
lung 888 892 5548 5552 O
or 893 895 5553 5555 O
mediastinum 896 907 5556 5567 O
within 908 914 5568 5574 O
3 915 916 5575 5576 B-upper_bound
months 917 923 5577 5583 I-upper_bound
prior 924 929 5584 5589 I-upper_bound
to 930 932 5590 5592 O
lymphodepleting 933 948 5593 5608 O
chemotherapy 949 961 5609 5621 O
; 961 962 5621 5622 O
however 963 970 5623 5630 O
, 970 971 5630 5631 O
electron 972 980 5632 5640 B-treatment
beam 981 985 5641 5645 I-treatment
radiotherapy 986 998 5646 5658 I-treatment
to 999 1001 5659 5661 O
superficial 1002 1013 5662 5673 O
structures 1014 1024 5674 5684 O
in 1025 1027 5685 5687 O
the 1028 1031 5688 5691 O
chest 1032 1037 5692 5697 O
is 1038 1040 5698 5700 O
permitted 1041 1050 5701 5710 O

Subject 0 7 5711 5718 O
must 8 12 5719 5723 O
have 13 17 5724 5728 O
adequate 18 26 5729 5737 O
organ 27 32 5738 5743 O
function 33 41 5744 5752 O
as 42 44 5753 5755 O
indicated 45 54 5756 5765 O
by 55 57 5766 5768 O
the 58 61 5769 5772 O
following 62 71 5773 5782 O
laboratory 72 82 5783 5793 O
values 83 89 5794 5800 O
: 89 90 5800 5801 O
a 91 92 5802 5803 O
) 92 93 5803 5804 O
Absolute 94 102 5805 5813 B-clinical_variable
Neutrophil 103 113 5814 5824 I-clinical_variable
count 114 119 5825 5830 I-clinical_variable
( 120 121 5831 5832 I-clinical_variable
ANC 121 124 5832 5835 I-clinical_variable
) 124 125 5835 5836 I-clinical_variable
> 126 127 5837 5838 O
= 127 128 5838 5839 O
1.0 128 131 5839 5842 B-lower_bound
x10 132 135 5843 5846 I-lower_bound
^ 135 136 5846 5847 I-lower_bound
9 136 137 5847 5848 I-lower_bound
per 138 141 5849 5852 I-lower_bound
liter 142 147 5853 5858 I-lower_bound
( 148 149 5859 5860 I-lower_bound
/L 149 151 5860 5862 I-lower_bound
) 151 152 5862 5863 I-lower_bound
( 153 154 5864 5865 O
without 154 161 5865 5872 O
G 162 163 5873 5874 O
- 163 164 5874 5875 O
CSF 164 167 5875 5878 O
support 168 175 5879 5886 O
) 175 176 5886 5887 O
; 176 177 5887 5888 O
b 178 179 5889 5890 O
) 179 180 5890 5891 O
Platelets 181 190 5892 5901 B-clinical_variable
> 191 192 5902 5903 O
= 192 193 5903 5904 O
75 194 196 5905 5907 B-lower_bound
x10 197 200 5908 5911 I-lower_bound
^ 200 201 5911 5912 I-lower_bound
9 201 202 5912 5913 I-lower_bound
/ 202 203 5913 5914 I-lower_bound
L 203 204 5914 5915 I-lower_bound
; 204 205 5915 5916 O
c 206 207 5917 5918 O
) 207 208 5918 5919 O
Hemoglobin 209 219 5920 5930 B-clinical_variable
> 220 221 5931 5932 O
80 221 223 5932 5934 B-lower_bound
grams 224 229 5935 5940 I-lower_bound
per 230 233 5941 5944 I-lower_bound
deciliter 234 243 5945 5954 I-lower_bound
( 244 245 5955 5956 I-lower_bound
g 245 246 5956 5957 I-lower_bound
/ 246 247 5957 5958 I-lower_bound
dL 247 249 5958 5960 I-lower_bound
) 249 250 5960 5961 I-lower_bound
( 251 252 5962 5963 O
without 252 259 5963 5970 O
transfusion 260 271 5971 5982 O
support 272 279 5983 5990 O
within 280 286 5991 5997 O
7 287 288 5998 5999 B-upper_bound
days 289 293 6000 6004 I-upper_bound
from 294 298 6005 6009 O
start 299 304 6010 6015 O
of 305 307 6016 6018 O
leukapheresis 308 321 6019 6032 B-treatment
) 321 322 6032 6033 O
; 322 323 6033 6034 O
d 324 325 6035 6036 O
) 325 326 6036 6037 O
Prothrombin 327 338 6038 6049 B-clinical_variable
Time 339 343 6050 6054 I-clinical_variable
or 344 346 6055 6057 I-clinical_variable
International 347 360 6058 6071 I-clinical_variable
Normalized 361 371 6072 6082 I-clinical_variable
Ratio 372 377 6083 6088 I-clinical_variable
( 378 379 6089 6090 I-clinical_variable
INR 379 382 6090 6093 I-clinical_variable
) 382 383 6093 6094 I-clinical_variable
< 384 385 6095 6096 O
= 385 386 6096 6097 O
1.5 386 389 6097 6100 B-upper_bound
times 390 395 6101 6106 I-upper_bound
upper 396 401 6107 6112 I-upper_bound
limit 402 407 6113 6118 I-upper_bound
of 408 410 6119 6121 I-upper_bound
normal 411 417 6122 6128 I-upper_bound
( 418 419 6129 6130 I-upper_bound
ULN 419 422 6130 6133 I-upper_bound
) 422 423 6133 6134 I-upper_bound
unless 424 430 6135 6141 O
receiving 431 440 6142 6151 O
therapeutic 441 452 6152 6163 B-treatment
anticoagulation 453 468 6164 6179 I-treatment
. 468 469 6179 6180 O
e 470 471 6181 6182 O
) 471 472 6182 6183 O
Partial 473 480 6184 6191 B-clinical_variable
Thromboplastin 481 495 6192 6206 I-clinical_variable
Time 496 500 6207 6211 I-clinical_variable
( 501 502 6212 6213 I-clinical_variable
PTT 502 505 6213 6216 I-clinical_variable
) 505 506 6216 6217 I-clinical_variable
< 507 508 6218 6219 O
= 508 509 6219 6220 O
1.5 509 512 6220 6223 O
times 513 518 6224 6229 O
upper 519 524 6230 6235 O
limit 525 530 6236 6241 O
of 531 533 6242 6244 O
normal 534 540 6245 6251 O
( 541 542 6252 6253 O
ULN 542 545 6253 6256 O
) 545 546 6256 6257 O
unless 547 553 6258 6264 O
receiving 554 563 6265 6274 O
therapeutic 564 575 6275 6286 O
anticoagulation 576 591 6287 6302 O
. 591 592 6302 6303 O
f 593 594 6304 6305 O
) 594 595 6305 6306 O
Calculated 596 606 6307 6317 B-clinical_variable
or 607 609 6318 6320 I-clinical_variable
measured 610 618 6321 6329 I-clinical_variable
creatinine 619 629 6330 6340 I-clinical_variable
clearance 630 639 6341 6350 I-clinical_variable
> 640 641 6351 6352 O
= 641 642 6352 6353 O
40 642 644 6353 6355 B-lower_bound
milliliters 645 656 6356 6367 I-lower_bound
per 657 660 6368 6371 I-lower_bound
minute 661 667 6372 6378 I-lower_bound
( 668 669 6379 6380 I-lower_bound
mL 669 671 6380 6382 I-lower_bound
/ 671 672 6382 6383 I-lower_bound
min 672 675 6383 6386 I-lower_bound
) 675 676 6386 6387 I-lower_bound
; 676 677 6387 6388 O
g 678 679 6389 6390 O
) 679 680 6390 6391 O
Serum 681 686 6392 6397 B-clinical_variable
total 687 692 6398 6403 I-clinical_variable
bilirubin 693 702 6404 6413 I-clinical_variable
< 703 704 6414 6415 O
= 704 705 6415 6416 O
1.5 705 708 6416 6419 B-upper_bound
times 709 714 6420 6425 I-upper_bound
ULN 715 718 6426 6429 I-upper_bound
( 719 720 6430 6431 O
unless 720 726 6431 6437 O
subject 727 734 6438 6445 O
had 735 738 6446 6449 O
documented 739 749 6450 6460 O
Gilbert 750 757 6461 6468 B-chronic_disease
's 757 759 6468 6470 I-chronic_disease
Syndrome 760 768 6471 6479 I-chronic_disease
) 768 769 6479 6480 O
; 769 770 6480 6481 O
h 771 772 6482 6483 O
) 772 773 6483 6484 O
Alanine 774 781 6485 6492 B-clinical_variable
aminotransferase 782 798 6493 6509 I-clinical_variable
( 799 800 6510 6511 I-clinical_variable
ALT)/Serum 800 810 6511 6521 I-clinical_variable
Glutamic 811 819 6522 6530 I-clinical_variable
Pyruvic 820 827 6531 6538 I-clinical_variable
Transaminase 828 840 6539 6551 I-clinical_variable
( 841 842 6552 6553 I-clinical_variable
SGPT 842 846 6553 6557 I-clinical_variable
) 846 847 6557 6558 I-clinical_variable
< 848 849 6559 6560 O
= 849 850 6560 6561 O
2.5 850 853 6561 6564 B-upper_bound
times 854 859 6565 6570 I-upper_bound
ULN 860 863 6571 6574 I-upper_bound

Subject 0 7 6575 6582 O
who 8 11 6583 6586 O
has 12 15 6587 6590 O
had 16 19 6591 6594 O
cytotoxic 20 29 6595 6604 B-treatment
chemotherapy 30 42 6605 6617 I-treatment
within 43 49 6618 6624 O
2 50 51 6625 6626 B-upper_bound
weeks 52 57 6627 6632 I-upper_bound
prior 58 63 6633 6638 I-upper_bound
to 64 66 6639 6641 O
leukapheresis 67 80 6642 6655 B-treatment

Subject 0 7 6656 6663 O
's 7 9 6663 6665 O
tumor 10 15 6666 6671 B-cancer
( 16 17 6672 6673 O
either 17 23 6673 6679 O
an 24 26 6680 6682 O
archival 27 35 6683 6691 O
specimen 36 44 6692 6700 O
or 45 47 6701 6703 O
a 48 49 6704 6705 O
fresh 50 55 6706 6711 O
biopsy 56 62 6712 6718 B-treatment
if 63 65 6719 6721 O
archival 66 74 6722 6730 O
tissue 75 81 6731 6737 O
is 82 84 6738 6740 O
unavailable 85 96 6741 6752 O
) 96 97 6752 6753 O
has 98 101 6754 6757 O
been 102 106 6758 6762 O
pathologically 107 121 6763 6777 O
reviewed 122 130 6778 6786 O
by 131 133 6787 6789 O
an 134 136 6790 6792 O
Adaptimmune- 137 149 6793 6805 O
/ 150 151 6806 6807 O
GSK 152 155 6808 6811 O
- 155 156 6811 6812 O
designated 156 166 6812 6822 O
central 167 174 6823 6830 O
laboratory 175 185 6831 6841 O
confirming 186 196 6842 6852 O
NY 197 199 6853 6855 O
- 199 200 6855 6856 O
ESO-1 200 205 6856 6861 O
and/or 206 212 6862 6868 O
LAGE-1a 213 220 6869 6876 O
expression 221 231 6877 6887 O

Subjects 0 8 6888 6896 O
must 9 13 6897 6901 O
be 14 16 6902 6904 O
in 17 19 6905 6907 O
complete 20 28 6908 6916 O
remission 29 38 6917 6926 O
from 39 43 6927 6931 O
prior 44 49 6932 6937 O
malignancy 50 60 6938 6948 B-cancer
in 61 63 6949 6951 O
order 64 69 6952 6957 O
to 70 72 6958 6960 O
be 73 75 6961 6963 O
eligible 76 84 6964 6972 O
to 85 87 6973 6975 O
enter 88 93 6976 6981 O
the 94 97 6982 6985 O
study 98 103 6986 6991 O

Subjects 0 8 6992 7000 O
with 9 13 7001 7005 O
known 14 19 7006 7011 O
epidermal 20 29 7012 7021 O
growth 30 36 7022 7028 O
factor 37 43 7029 7035 O
receptor 44 52 7036 7044 O
( 53 54 7045 7046 O
EGFR 54 58 7046 7050 O
) 58 59 7050 7051 O
mutations 60 69 7052 7061 O
or 70 72 7062 7064 O
ALK 73 76 7065 7068 B-treatment
or 77 79 7069 7071 O
ROS1 80 84 7072 7076 O
gene 85 89 7077 7081 O
rearrangements 90 104 7082 7096 O
must 105 109 7097 7101 O
have 110 114 7102 7106 O
failed 115 121 7107 7113 O
( 122 123 7114 7115 O
disease 123 130 7115 7122 O
progression 131 142 7123 7134 O
[ 143 144 7135 7136 O
PD 144 146 7136 7138 O
] 146 147 7138 7139 O
or 148 150 7140 7142 O
unacceptable 151 163 7143 7155 O
toxicity 164 172 7156 7164 O
) 172 173 7164 7165 O
prior 174 179 7166 7171 B-treatment
EGFR 180 184 7172 7176 I-treatment
or 185 187 7177 7179 O
ALK 188 191 7180 7183 O
or 192 194 7184 7186 O
ROS1 195 199 7187 7191 B-treatment
tyrosine 200 208 7192 7200 I-treatment
kinase 209 215 7201 7207 I-treatment
inhibitor 216 225 7208 7217 I-treatment
, 225 226 7217 7218 O
respectively 227 239 7219 7231 O
( 240 241 7232 7233 O
PD 241 243 7233 7235 O
or 244 246 7236 7238 O
unacceptable 247 259 7239 7251 O
toxicity 260 268 7252 7260 O
) 268 269 7260 7261 O

Subjects 0 8 7262 7270 O
with 9 13 7271 7275 O
prior 14 19 7276 7281 O
history 20 27 7282 7289 O
of 28 30 7290 7292 O
brain 31 36 7293 7298 B-cancer
metastasis 37 47 7299 7309 I-cancer
who 48 51 7310 7313 O
have 52 56 7314 7318 O
undergone 57 66 7319 7328 O
local 67 72 7329 7334 B-treatment
therapy 73 80 7335 7342 I-treatment
( 81 82 7343 7344 O
i.e. 82 86 7344 7348 O
, 86 87 7348 7349 O
metastasectomy 88 102 7350 7364 B-treatment
and/or 103 109 7365 7371 I-treatment
radiation 110 119 7372 7381 I-treatment
) 119 120 7381 7382 O
and 121 124 7383 7386 O
show 125 129 7387 7391 O
no 130 132 7392 7394 O
evidence 133 141 7395 7403 O
of 142 144 7404 7406 O
local 145 150 7407 7412 O
recurrence 151 161 7413 7423 O
or 162 164 7424 7426 O
progression 165 176 7427 7438 O
over 177 181 7439 7443 O
the 182 185 7444 7447 O
past 186 190 7448 7452 B-upper_bound
3 191 192 7453 7454 I-upper_bound
months 193 199 7455 7461 I-upper_bound
prior 200 205 7462 7467 I-upper_bound
to 206 208 7468 7470 O
Screening 209 218 7471 7480 O
are 219 222 7481 7484 O
eligible 223 231 7485 7493 O

Toxicity 0 8 7494 7502 O
from 9 13 7503 7507 O
previous 14 22 7508 7516 B-treatment
anti 23 27 7517 7521 I-treatment
- 27 28 7521 7522 I-treatment
cancer 28 34 7522 7528 I-treatment
therapy 35 42 7529 7536 I-treatment
that 43 47 7537 7541 O
has 48 51 7542 7545 O
not 52 55 7546 7549 O
recovered 56 65 7550 7559 O
to 66 68 7560 7562 O
< 69 70 7563 7564 O
= 70 71 7564 7565 O
Grade 71 76 7565 7570 B-upper_bound
1 77 78 7571 7572 I-upper_bound
prior 79 84 7573 7578 O
to 85 87 7579 7581 O
enrollment 88 98 7582 7592 O
( 99 100 7593 7594 O
except 100 106 7594 7600 O
for 107 110 7601 7604 O
non 111 114 7605 7608 O
- 114 115 7608 7609 O
clinically 115 125 7609 7619 O
significant 126 137 7620 7631 O
toxicities 138 148 7632 7642 O
, 148 149 7642 7643 O
e.g. 150 154 7644 7648 O
, 154 155 7648 7649 O
alopecia 156 164 7650 7658 B-chronic_disease
, 164 165 7658 7659 O
vitiligo 166 174 7660 7668 B-chronic_disease
) 174 175 7668 7669 O
. 175 176 7669 7670 O
Subjects 177 185 7671 7679 O
with 186 190 7680 7684 O
existing 191 199 7685 7693 O
pneumonitis 200 211 7694 7705 B-chronic_disease
as 212 214 7706 7708 O
a 215 216 7709 7710 O
result 217 223 7711 7717 O
of 224 226 7718 7720 O
radiation 227 236 7721 7730 B-treatment
are 237 240 7731 7734 O
not 241 244 7735 7738 O
excluded 245 253 7739 7747 O
; 253 254 7747 7748 O
however 255 262 7749 7756 O
, 262 263 7756 7757 O
subjects 264 272 7758 7766 O
can 273 276 7767 7770 O
not 276 279 7770 7773 O
be 280 282 7774 7776 O
oxygen 283 289 7777 7783 O
dependent 290 299 7784 7793 O

Unintended 0 10 7794 7804 B-clinical_variable
weight 11 17 7805 7811 I-clinical_variable
loss 18 22 7812 7816 I-clinical_variable
> 23 24 7817 7818 O
10 24 26 7818 7820 B-lower_bound
% 26 27 7820 7821 I-lower_bound
in 28 30 7822 7824 O
6 31 32 7825 7826 B-upper_bound
months 33 39 7827 7833 I-upper_bound
preceding 40 49 7834 7843 O
study 50 55 7844 7849 O
entry 56 61 7850 7855 O

corticosteroids 0 15 7856 7871 B-treatment
or 16 18 7872 7874 O
any 19 22 7875 7878 O
other 23 28 7879 7884 O
immunosuppressive 29 46 7885 7902 B-treatment
therapy 47 54 7903 7910 I-treatment
within 55 61 7911 7917 O
2 62 63 7918 7919 B-upper_bound
weeks 64 69 7920 7925 I-upper_bound
prior 70 75 7926 7931 I-upper_bound
to 76 78 7932 7934 O
leukapheresis 79 92 7935 7948 B-treatment

